Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Target Price at $19.30

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $14.50.

NEO has been the subject of a number of recent research reports. Leerink Partners lowered NeoGenomics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $25.00 to $9.00 in a report on Wednesday, April 30th. The Goldman Sachs Group cut their price target on shares of NeoGenomics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. Morgan Stanley dropped their target price on shares of NeoGenomics from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 1st. Bank of America decreased their price target on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Finally, Leerink Partnrs cut NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 30th.

Institutional Trading of NeoGenomics

A number of hedge funds have recently made changes to their positions in NEO. SBI Securities Co. Ltd. bought a new stake in NeoGenomics in the 4th quarter worth approximately $26,000. Versant Capital Management Inc grew its stake in shares of NeoGenomics by 174.9% during the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after buying an additional 1,142 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 3,289 shares during the period. Smartleaf Asset Management LLC boosted its holdings in NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 2,787 shares during the period. Finally, Blue Trust Inc. increased its stake in NeoGenomics by 33.2% in the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock worth $73,000 after purchasing an additional 1,103 shares during the period. 98.50% of the stock is owned by institutional investors.

NeoGenomics Trading Up 1.8 %

NASDAQ NEO opened at $7.84 on Tuesday. NeoGenomics has a 52 week low of $6.08 and a 52 week high of $19.12. The business has a 50 day moving average price of $9.35 and a 200-day moving average price of $13.22. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -12.64 and a beta of 1.41.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The business had revenue of $168.04 million for the quarter, compared to analyst estimates of $171.38 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The business’s quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.02) EPS. As a group, equities analysts expect that NeoGenomics will post -0.2 earnings per share for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.